It's been a tough year for Gilead Sciences, Inc. (NASDAQ:GILD), with its stock going down as much as 20% year-to-date, but analysts think that the company's potential in Hepatitis C market makes it a strong candidate for a comeback in the near future. Moreover, sales of HIV drugs grew by double digits in the last quarter. Back in June, FDA approved Epclusa, Gilead's Hepatitis C treatment drug. The company reported second quarter EPS of $3.08 on $7.78 billion in revenue, versus the consensus estimates of $3.02 and $7.79 billion, respectively. Last week, Gilead's treatment of pulmonary arterial hypertension was granted orphan drug status by the FDA.